Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs.
The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation.
Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -2.86 Decreased by -1.58 K% | -3.19 Increased by +10.34% |
| Aug 8, 24 | -2.89 Decreased by -1.83 K% | -3.10 Increased by +6.77% |
| May 9, 24 | -2.83 Decreased by -1.31 K% | -2.88 Increased by +1.74% |
| Mar 7, 24 | -3.11 Decreased by -1.45 K% | -3.07 Decreased by -1.30% |
| Nov 9, 23 | -0.17 Increased by +19.05% | -0.14 Decreased by -21.43% |
| Aug 10, 23 | -0.15 Increased by +34.78% | -0.16 Increased by +6.25% |
| May 4, 23 | -0.20 Increased by 0.00% | -0.20 |
| Mar 9, 23 | -0.20 Decreased by -25.00% | -0.21 Increased by +4.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by -100.00% | -8.46 M Increased by +14.18% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 801.00 K Increased by +655.66% | -8.56 M Increased by +4.54% | Decreased by -1.07 K% Increased by +87.37% |
| Mar 31, 24 | 569.00 K Increased by +180.30% | -8.39 M Increased by +26.93% | Decreased by -1.47 K% Increased by +73.93% |
| Dec 31, 23 | 297.00 K Increased by +73.68% | -9.16 M Increased by +15.81% | Decreased by -3.09 K% Increased by +51.53% |
| Sep 30, 23 | 179.00 K Decreased by -53.14% | -9.86 M Increased by +8.05% | Decreased by -5.51 K% Decreased by -96.24% |
| Jun 30, 23 | 106.00 K Decreased by -44.50% | -8.97 M Increased by +22.93% | Decreased by -8.46 K% Decreased by -38.88% |
| Mar 31, 23 | 203.00 K Increased by +N/A% | -11.48 M Decreased by -16.09% | Decreased by -5.65 K% Decreased by N/A% |
| Dec 31, 22 | 171.00 K Decreased by -69.24% | -10.88 M Decreased by -34.83% | Decreased by -6.37 K% Decreased by -338.40% |